Prescription drug · NDA
Tazverik (Tazemetostat) NDC 72607-100
Tazemetostat hydrobromide 200 mg/1 · Tablet, Film coated · Oral · Epizyme, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72607-100-00 | 72607010000 | 240 TABLET, FILM COATED in 1 BOTTLE (72607-100-00)Marketed from Jan 23, 2020 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tazverik
- Generic name (nonproprietary)
- tazemetostat
- Active ingredients
- Tazemetostat hydrobromide — 200 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Epizyme, Inc.NDC labeler code 72607
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 211723
- Marketing start
- Marketing end
- Other FDA classes
- Methyltransferase Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 1 Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 2 K Inhibitors (Mechanism)
- Identifiers
- Product ID 72607-100_c4bd8d8a-22c1-4911-a9b4-7368582d8e5dSPL ID c4bd8d8a-22c1-4911-a9b4-7368582d8e5dSPL set ID 7db07b5f-4e22-467c-9c0a-f830b08dbb1dRxCUI 2274384, 2274390UNII 6P89T5M073
- Pharmacologic class
- Methyltransferase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N472607010000followed by a unit qualifier and the quantityPackage 72607-0100-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approv…
Excerpt only. Read the full label for complete information.
About NDC 72607-100
- What is NDC 72607-100?
- 72607-100 is the product NDC for Tazverik (tazemetostat), Tazemetostat hydrobromide 200 mg/1 tablet, film coated, listed with the FDA by Epizyme, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tazverik (Tazemetostat).
- What is the active ingredient?
- Tazemetostat hydrobromide.
- Who is the labeler?
- Epizyme, Inc., NDC labeler code 72607. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tazverik?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.